Hikari Power Ltd Has $2.34 Million Position in Dynavax Technologies Corporation (DVAX)

Hikari Power Ltd increased its stake in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 29.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,755 shares of the biopharmaceutical company’s stock after buying an additional 25,000 shares during the quarter. Hikari Power Ltd owned about 0.18% of Dynavax Technologies Corporation worth $2,338,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Bank of America Corp DE grew its position in Dynavax Technologies Corporation by 2.3% during the first quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 456 shares in the last quarter. Nationwide Fund Advisors grew its position in Dynavax Technologies Corporation by 2.5% during the second quarter. Nationwide Fund Advisors now owns 28,359 shares of the biopharmaceutical company’s stock worth $274,000 after buying an additional 692 shares in the last quarter. Parametric Portfolio Associates LLC grew its position in Dynavax Technologies Corporation by 3.6% during the first quarter. Parametric Portfolio Associates LLC now owns 27,151 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 939 shares in the last quarter. American International Group Inc. grew its position in Dynavax Technologies Corporation by 7.1% during the first quarter. American International Group Inc. now owns 23,934 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 1,584 shares in the last quarter. Finally, Patriot Financial Group Insurance Agency LLC grew its position in Dynavax Technologies Corporation by 16.5% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 1,700 shares in the last quarter. 58.55% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have weighed in on DVAX shares. Royal Bank Of Canada set a $7.00 target price on Dynavax Technologies Corporation and gave the company a “hold” rating in a report on Wednesday, July 26th. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies Corporation in a report on Thursday, July 27th. Cowen and Company reaffirmed an “outperform” rating and issued a $30.00 target price on shares of Dynavax Technologies Corporation in a report on Thursday, August 10th. Cantor Fitzgerald started coverage on Dynavax Technologies Corporation in a report on Friday, September 15th. They issued an “overweight” rating and a $24.00 target price on the stock. Finally, ValuEngine raised Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a report on Thursday, September 7th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Dynavax Technologies Corporation has an average rating of “Buy” and an average price target of $25.17.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://transcriptdaily.com/2017/11/17/hikari-power-ltd-has-2-34-million-position-in-dynavax-technologies-corporation-dvax.html.

Shares of Dynavax Technologies Corporation (NASDAQ DVAX) traded up $0.60 during mid-day trading on Friday, hitting $18.45. The company’s stock had a trading volume of 1,868,800 shares, compared to its average volume of 1,897,669. Dynavax Technologies Corporation has a 52-week low of $3.70 and a 52-week high of $24.45.

Dynavax Technologies Corporation (NASDAQ:DVAX) last issued its earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.53) by $0.15. Dynavax Technologies Corporation had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The firm had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.28 million. During the same quarter last year, the business posted ($0.90) EPS. The company’s revenue was down 68.8% compared to the same quarter last year. equities research analysts expect that Dynavax Technologies Corporation will post -1.72 earnings per share for the current year.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Corporation (NASDAQ:DVAX).

Institutional Ownership by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply